Advanced Cell Technology Announces Alternative Approach for Derivation of Embryonic Stem Cell Lines

Approach Maintains Developmental Potential of Embryo

Worcester, MA – Advanced Cell Technology, Inc (OTC Bulletin Board: ACTC.OB) reported today the generation of embryonic stem cell lines using an alternative approach that does not interfere with the developmental potential of embryos. The research, which appears online (ahead of print) in the journal Nature, by ACT and its collaborators, describes a method of deriving stem cells in mice using a technique of single-cell embryo biopsy similar to that used in preimplantation genetic diagnosis (PGD) to test for genetic defects.

“The most basic objection to embryonic stem cell research is the fact that embryos are deprived of any further potential to develop into a complete human being,” said Robert Lanza, Medical Director at ACT, and senior author of the study. “We have shown in a mouse model that you can generate embryonic stem cells using a method that does not interfere with the developmental potential of the embryo. It is important to note that this work was performed in the mouse and needs to be extended to the human species. It would be tragic not to pursue all options and methods available to us to get this technology to the bedside as soon as possible,” added Lanza.

Five embryonic stem (ES) cells and seven extraembryonic (trophoblast) stem cell lines were produced from single mouse blastomeres, which maintained normal karyotype (chromosome type) and markers of pluripotency or TS cells for up to more than 50 passages. The ES cells differentiated into derivatives of all three germ layers both in vitro and in chimeric offspring and teratomas. Single-blastomere-biopsied embryos developed to term without a reduction in their developmental capacity. These results are consistent with human data, which indicate that normal and PGD-biopsied embryos develop into blastocysts with comparable efficiency.

“In the past, stem cell lines have been isolated from the inner cell mass of blastocysts and in a few instances, from earlier, cleavage-stage embryos” said Young Chung, Senior Scientist at ACT, and first author of the paper. “We generated five ES and seven trophoblast stem (TS) cell lines from single mouse embryo cells. The stem cells were able to generate all the cell types of body, including nerve cells, bone, and beating heart.”

“Ultimately the goal of stem cell research is to provide new treatments for what are now incurable diseases,” added Michael West, President & Chief Scientific Officer at ACT. “Therefore, it is important to emphasize that these advances do not obviate the need of medical researchers to pursue somatic cell nuclear transfer and other related technologies that have so much potential in the emerging field of regenerative medicine.”

The researchers of the paper from Advanced Cell Technology collaborated with scientists from the University of Wisconsin, Madison, Wisconsin. The paper’s other authors are Irina Klimanskaya, Sandy Becker, and Shu-Jiang Lu of ACT; Joel Marh, currently at PrimeGen biotech, LLC, Irvine, California; and Julie John and Lorraine Meisner of the University of Wisconsin. Irina Klimanskaya, Sandy Becker, and Young Chung of Advanced Cell Technology contributed equally to the work.

Advanced Cell Technology, Inc is a leading biotechnology company in the emerging field of regenerative medicine.

The paper can be viewed in its entirety at “http://www.advancedcell.com”:http://www.advancedcell.com.

Editor’s Note
VNR will include an interview with ACT scientist Robert Lanza, M.D. Vice President of Medical & Scientific Development, along with b-roll of the scientific team in the ACT laboratory working with embryonic stem cells.

*Click Here to download VNR including interview with Robert Lanza and b-roll of scientific team in the ACT Laboratory:*
“Dr. Robert Lanza Interview VNR and Laboratory B-roll”:http://www.advancedcell.com/media-gallery-item/interview-with-dr-robert-lanza–biopsy-procedure

*Satellite coordinates:*
IA6 Transponder 15
C Band Analog.
(I= Intel Sat)
Downlink freq. 4000 v

*Satellite Feed Availability:*
Sun 10/16: 1:00 pm – 1:15pm EST
Mon 10/17: 10:00am – 10:15am EST
Mon 10/17: 1:30pm – 1:45pm EST

About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., a Nevada corporation, is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company is currently headquartered in Worcester, Massachusetts. For more information about the company visit  http://www.advancedcell.com.

Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and its subsidiary, Advanced Cell, Inc., and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2005. 

Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Press Contact

Jordan Markwith, Chad Griffin
310-888-3523